ReviewJournal of thoracic disease2025
Novel insights into diagnosis and management of hyperreactivity: a narrative review.
Review in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Hyperreactivity (HR) refers to an exaggerated biological response to a given stimulus that is within the normal physiological range, resulting from a lowered activation threshold of the involved system or effector cells. It commonly occurs after surgery, lung transplantation, and coronavirus disease 2019 (COVID-19) infection but lacks a unified concept and systematic understanding. This review aims to elucidate the concept, mechanisms, and disease spectrum of HR as an independent clinical entity, systematically explore its roles in postoperative conditions, lung transplantation, and COVID-19, and develop a biomarker-based hierarchical management framework, thereby providing a new paradigm for its precise recognition and intervention. Methods: We systematically searched the PubMed, Web of Science, Scopus, and China National Knowledge Infrastructure databases for literature published from January 1, 1968, to November 1, 2025, including reviews, randomized controlled trials, and observational studies, human or animal studies related to HR mechanisms or clinical phenotypes, while excluding non-peer-reviewed materials such as case reports and conference abstracts. Key Content and Findings: This study first proposes that HR arises from a four-dimensional imbalance across the nervous, endocrine, immune, and microenvironmental systems, characterized by thoroughness, early onset/persistence, and individual variability. The mechanisms underlying HR in postoperative, transplant-related, and COVID-19 conditions are systematically summarized, and a hierarchical, biomarker-based management framework is developed, highlighting the need for marker validation and trajectory modeling. Conclusions: HR represents an independent clinical entity that transcends traditional disease boundaries. This review provides a new paradigm for its precise recognition and intervention and is expected to advance the conceptual and practical development of this field. Future research, clinical practice, and policy formulation should be individualized and mechanism-driven.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.